SCHEMBL3070233

SCHEMBL3070233

Clc1cc(-c2nc(CN3CCCCC3)co2)ccc1OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.56
DRD4 P21917 5/20 0.56
DRD3 P35462 5/20 0.56
HRH3 Q9Y5N1 3/20 0.51
HTR2A P28223 1/20 0.45
HRH1 P35367 1/20 0.45
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ABCB1 P08183 2/20 0.43
ABCC1 P33527 1/20 0.43
KCNH2 Q12809 1/20 0.43
SCN9A Q15858 1/20 0.43
CD274 Q9NZQ7 1/20 0.42
LTA4H P09960 1/20 0.42
AURKA O14965 1/20 0.40
ERBB2 P04626 1/20 0.40
NPY1R P25929 1/20 0.40
S1PR1 P21453 1/20 0.40
PTGER1 P34995 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3066306 0.88 DRD2 (0.53) DRD2DRD4DRD3HRH3HTR2A
SCHEMBL3065720 0.85 HRH3 (0.59) DRD2DRD4DRD3HRH3HTR2A
SCHEMBL3079159 0.77 HRH3 (0.54) DRD2DRD4DRD3HRH3HTR2A
SCHEMBL3066616 0.76 HRH3 (0.55) HRH3HRH1KCNH2
SCHEMBL5185637 0.76 HTR2C (0.41)
SCHEMBL4270619 0.74 KDM4E (0.49) DRD2DRD4DRD3PTGER1
SCHEMBL3070986 0.73 HRH3 (0.58) DRD2DRD4DRD3HRH3HTR2A
SCHEMBL4639757 0.73 MEN1 (0.52) DRD2DRD4DRD3MEN1KMT2A
SCHEMBL3087050 0.73 HRH3 (0.57) DRD2DRD4DRD3HRH3ABCB1
SCHEMBL3082257 0.71 HRH3 (0.70) DRD2DRD4DRD3HRH3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US claimed
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 US disclosed
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 US disclosed
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 US disclosed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US disclosed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US disclosed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses OXER1, OXTR, OGFR DRD2 930/4885DRD4 863/4885DRD3 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.